{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:23:01Z","timestamp":1793107381674,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T00:00:00Z","timestamp":1694304000000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.autrev.2023.103276","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T02:12:01Z","timestamp":1673662321000},"page":"103276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["JAK inhibitors and autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"22","author":[{"given":"Maurizio","family":"Benucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juela","family":"Levani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Economou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edda","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Amedei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103276_bb0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The regulation of JAKs in cytokine signaling and its breakdown in disease","volume":"118","author":"Hammaren","year":"2019","journal-title":"Cytokine"},{"issue":"27","key":"10.1016\/j.autrev.2023.103276_bb0010","doi-asserted-by":"crossref","first-page":"25760","DOI":"10.1074\/jbc.M500822200","article-title":"The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak\/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression","volume":"280","author":"Radtke","year":"2005","journal-title":"J Biol Chem"},{"issue":"39","key":"10.1016\/j.autrev.2023.103276_bb0015","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1074\/jbc.M109.011387","article-title":"A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation","volume":"284","author":"Zhao","year":"2009","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.autrev.2023.103276_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2","volume":"21","author":"Wallweber","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"21","key":"10.1016\/j.autrev.2023.103276_bb0025","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"Constantinescu S.N: JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.autrev.2023.103276_bb0030","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"49","key":"10.1016\/j.autrev.2023.103276_bb0035","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.autrev.2023.103276_bb0040","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6544","key":"10.1016\/j.autrev.2023.103276_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"issue":"5237","key":"10.1016\/j.autrev.2023.103276_bb0050","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.autrev.2023.103276_bb0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bcp.2005.12.017","article-title":"JAK\/STAT signal transduction: regulators and implication in hematological malignancies","volume":"71","author":"Valentino","year":"2006","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103276_bb0060","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103276_bb0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The Jakinibs in systemic lupus erythematosus: progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.autrev.2023.103276_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102750","article-title":"Working and safety profiles of JAK\/STAT signaling inhibitors. Are these small molecules also smart?","volume":"20","author":"Favoino","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2023.103276_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2023.103276_bb0080","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103276_bb0085","first-page":"454","article-title":"A platelet\u2019s guide to synovitis","volume":"21","author":"Cafaro","year":"2019","journal-title":"Isr Med Assoc J"},{"issue":"7","key":"10.1016\/j.autrev.2023.103276_bb0090","doi-asserted-by":"crossref","first-page":"103120","DOI":"10.1016\/j.autrev.2022.103120","article-title":"Significance of IL-7 and IL-7R in RA and autoimmunity","volume":"21","author":"Meyer","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2023.103276_bb0095","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/ar2284","article-title":"Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease","volume":"9","author":"Wuttge","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2023.103276_bb0100","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.pathol.2016.06.001","article-title":"Interleukin-15 as a potential new target in Sj\u00f6gren\u2019s syndrome-associated inflammation","volume":"48","author":"Sisto","year":"2016","journal-title":"Pathology."},{"issue":"5","key":"10.1016\/j.autrev.2023.103276_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102508","article-title":"Precision health: a pragmatic approach to understanding and addressing key factors in autoimmune diseases","volume":"19","author":"Conrad","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2023.103276_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102738","article-title":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019 consensus","volume":"20","author":"Giacomelli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103276_bb0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103276_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103031","article-title":"Methotrexate in early rheumatoid arthritis: is the anchor drug still holding?","volume":"21","author":"Giollo","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103276_bb0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103276_bb0130","doi-asserted-by":"crossref","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377\u201386. (doi:101056\/NEJMoa1310476 2014).","DOI":"10.1056\/NEJMoa1310476"},{"key":"10.1016\/j.autrev.2023.103276_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103276_bb0140","first-page":"3927","article-title":"Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study","volume":"67","author":"Taylor","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0145","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103276_bb0150","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0155","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A Phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0160","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0165","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103276_bb0170","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103276_bb0175","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103276_bb0180","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103276_bb0185","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103276_bb0190","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2023.103276_bb0200","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103276_bb0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","article-title":"Oral tofacitinib citrate for recalcitrant cutaneous lupus","volume":"20","author":"Bonnardeaux","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.autrev.2023.103276_bb0215","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2023.103276_bb0220","article-title":"Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103276_bb0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2023.103276_bb0230","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","article-title":"Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus","volume":"81","author":"D\u00f6rner","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103276_bb0235","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103276_bb0245","article-title":"Resolution of accelerated nodulosis with upadacitinib in a patient with systemic lupus erythematosus and Jaccoud\u2019s arthropathy","author":"Michailidou","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0255","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.drudis.2021.06.010","article-title":"IFN-\u03b1: a key therapeutic target for multiple autoimmune rheumatic diseases","volume":"26","author":"De Ceuninck","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.autrev.2023.103276_bb0260","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103276_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.autrev.2023.103276_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: a systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103276_bb0275","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.2792","article-title":"Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj\u00f6gren\u2019s syndrome","volume":"45","author":"Mariette","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2023.103276_bb0280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/gene.2008.94","article-title":"Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Nordmark","year":"2009","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2023.103276_bb0285","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103276_bb0290","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/eji.201747213","article-title":"Aberrant cell signalling in PBMCs upon IFN-\u03b1 stimulation in primary Sj\u00f6gren\u2019s syndrome patients associates with type I interferon signature","volume":"48","author":"Davies","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2023.103276_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00281","article-title":"Single cell based phosphorylation profiling identifies alterations in Toll-like receptor 7 and 9 signaling in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103276_bb0300","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.autrev.2016.09.001","article-title":"Dry eye disease and uveitis: a closer look at immune mechanisms in animal models of two ocular autoimmune diseases","volume":"15","author":"Bose","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103276_bb0305","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"SHM","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2023.103276_bb0310","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.autrev.2023.103276_bb0315","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/annrheumdis-2021-222053","article-title":"Pilot study of baricitinib for active Sjogren\u2019s syndrome","volume":"81","author":"Bai","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103276_bb0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/path.4355","article-title":"Sustained autoimmune mechanisms in dermatomyositis","volume":"233","author":"Greenberg","year":"2014","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103276_bb0325","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2023.103276_bb0330","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2023.103276_bb0335","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/key425","article-title":"CD4+ CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103276_bb0340","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2023.103276_bb0345","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103276_bb0350","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103276_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103276_bb0360","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","author":"Siamak Moghadam-Kia","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103276_bb0365","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib \u2013 a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2023.103276_bb0370","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000000807","article-title":"Tofacitinib for the treatment of refractory polymyositis","author":"Babaoglu","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103276_bb0375","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2023.103276_bb0380","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","article-title":"Recent advances in our understanding of giant cell arteritis pathogenesis","volume":"16","author":"Samson","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103276_bb0385","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.revmed.2017.06.016","article-title":"De la physiopathologie de l\u2019art\u00e9rite \u00e0 cellules g\u00e9antes aux nouvelles cibles th\u00e9rapeutiques","volume":"38","author":"Samson","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2023.103276_bb0390","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103276_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.635663","article-title":"Contribution of janus-kinase\/signal transduction activator of transcription pathway in the pathogenesis of vasculitis: a possible treatment target in the upcoming future","volume":"12","author":"Bursi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2023.103276_bb0400","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41927-017-0004-5","article-title":"Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets","volume":"1","author":"Koster","year":"2017","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2023.103276_bb0405","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2023.103276_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:01Z","timestamp":1761600481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1568997223000101"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103276","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors and autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103276"}}